orantinib has been researched along with semaxinib in 26 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (semaxinib) | Trials (semaxinib) | Recent Studies (post-2010) (semaxinib) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 480 | 31 | 218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 21 (80.77) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, C; McMahon, G; Rice, A; Schreck, R; Shawver, LK; Sun, L; Tang, C; Tang, F; Tran, N; Waltz, K | 1 |
| Chen, H; Chu, JY; Cui, J; Fukuda, JY; Liang, C; Luu, TC; Miller, T; Nematalla, A; Shirazian, S; Sistla, A; Sun, L; Tang, C; Tang, F; Wang, X; Wei, J; Zhou, Y | 1 |
| Jagarlapudi, SA; Narasu, L; Rambabu, G; Sanam, R; Tajne, S; Vadivelan, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gangjee, A; Ihnat, MA; Kurup, S; Shenoy, SS; Thorpe, JE | 1 |
| Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
| Albitar, M; Cherrington, JM; Giles, FJ; Smolich, BD; West, KA; Yuen, HA | 1 |
| Honsawek, S; Kiewlich, D; Krystal, GW; Liang, C; Lipson, KE; McMahon, G; Sun, L; Vasile, S | 1 |
| Kuwano, M; Ono, M | 1 |
| Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC | 1 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Ellis, LM | 1 |
| Alileche, A | 1 |
| Bergers, G; Bergsland, E; Hanahan, D; Meyer-Morse, N; Song, S | 1 |
| Abdollahi, A; Debus, J; Hahnfeldt, P; Han, X; Hlatky, L; Howlett, AR; Huber, PE; Krempien, R; Lipson, KE; Trinh, T; Weber, KJ | 1 |
| Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Evan, GI; Fox, SB; Harris, AL; Knies-Bamforth, UE; Poulsom, R | 1 |
| Advani, AS | 1 |
| Abbruzzese, JL; Davis, DW; Demetri, GD; Herbst, RS; Heymach, JV; McConkey, DJ; Rashid, A; Raut, CP; Shen, Y; Stadler, WM; Takamori, R; Wen, S; Xiong, HQ | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q | 1 |
| Elitzsch, A; Laschke, MW; Menger, MD; Vajkoczy, P; Vollmar, B | 1 |
| Chung, HK; Hwang, JH; Jo, KW; Jo, YS; Jung, HS; Kim, DW; Kweon, GR; Lee, SJ; Park, KC; Park, SH; Rha, SY; Shong, M; Song, JH | 1 |
| Grosicka, A; Grosicki, S; Hołowiecki, J | 1 |
| Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H | 1 |
5 review(s) available for orantinib and semaxinib
| Article | Year |
|---|---|
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles | 2002 |
A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Colorectal Neoplasms; Endothelial Growth Factors; Extracellular Matrix; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; Lymphokines; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
C-kit as a target in the treatment of acute myelogenous leukemia.
Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor | 2005 |
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2007 |
1 trial(s) available for orantinib and semaxinib
| Article | Year |
|---|---|
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate | 2005 |
20 other study(ies) available for orantinib and semaxinib
| Article | Year |
|---|---|
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Topics: Drug Design; Drug Evaluation, Preclinical; Endothelial Growth Factors; Enzyme Inhibitors; Fibroblast Growth Factors; Humans; Indoles; Lymphokines; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Platelet-Derived Growth Factor; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosi
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biological Availability; Enzyme Inhibitors; Indoles; Mice; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solubility; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Topics: Computer Simulation; Drug Design; Inhibitory Concentration 50; Models, Chemical; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Small Molecule Libraries; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Diamines; Indoles; Male; Melanoma; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Pyrimidines; Pyrimidinones; Pyrroles; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Humans; Indoles; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Oxindoles; Phosphorylation; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrroles; Stem Cell Factor; Tumor Cells, Cultured | 2001 |
Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Topics: Animals; Carcinoma, Small Cell; Cell Division; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Indoles; Lung Neoplasms; Models, Molecular; Oxindoles; Phosphorylation; Propionates; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
Interleukin-2 and cancer: critical analysis of results, problems and expectations.
Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2 | 2003 |
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Islet Cell; Endothelium, Vascular; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2003 |
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kinetics; Lymphokines; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxindoles; Particle Accelerators; Propionates; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; X-Rays | 2003 |
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Topics: Animals; Cell Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Keratinocytes; Mice; Neovascularization, Physiologic; Oxindoles; Papilloma; Precancerous Conditions; Propionates; Proto-Oncogene Proteins c-myc; Pyrroles; RNA, Messenger; Skin; Skin Neoplasms; Tamoxifen; Transcription Factors; Transgenes; Vascular Endothelial Growth Factor A | 2004 |
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cricetinae; Endometriosis; Endometrium; Female; Fibroblast Growth Factors; Indoles; Mesocricetus; Neovascularization, Pathologic; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Uterine Diseases; Vascular Endothelial Growth Factor A | 2006 |
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Indoles; Mice; NIH 3T3 Cells; Oxindoles; Phosphorylation; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2006 |
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2008 |